6.7 Physical
Main inclusion criteria
Testing and evaluation of physical interventions in humans in a clinical, community or applied setting including:
- physical therapies, physiotherapy, occupational therapy, speech therapy, dietetics, osteopathy and exercise
Advice on research activities
Includes physical therapies such as temperature and increased oxygen levels.
Excludes studies of nutritional supplements which should be coded as 6.1 Pharmaceuticals.
Official terminology
|
Full name of code |
Short name | Unique ID |
| 6.7 Physical | 6.7 Physical |
HRCS_RA_6_7 |
Related external links
Common Scientific Outline (CSO) – 5.6 Complementary and Alternative Treatment Approaches
Advice on research activities
Following changes in EU legislation, nutritional and vitamin supplements are treated as pharmaceuticals. Therapeutic studies involving these substances should be coded as 5.1 Pharmaceuticals or 6.1 Pharmaceuticals.
Studies of the preventive effects of nutritional supplements should be coded as 3.3 Nutrition.
Main inclusion criteria
Development of physical interventions including:
- physical therapies, physiotherapy, occupational therapy, speech therapy, dietetics, exercise and osteopathy
- mechanisms of action
- testing in model systems
Advice on research activities
Excludes studies of nutritional supplements which should be coded as 5.1 Pharmaceuticals.
Official terminology
|
Full name of code |
Short name | Unique ID |
| 5.7 Physical | 5.7 Physical |
HRCS_RA_5_7 |
Related external links
Common Scientific Outline (CSO) – 5.6 Complementary and Alternative Treatment Approaches
Main inclusion criteria
Identification and development of pharmaceutical small molecules, therapeutic vaccines, antibodies and hormones including:
- drug screening and development of delivery systems
- mechanism of action including side effects and drug resistance
- pharmacogenetics, prediction of genetic variation and responses to drugs
- testing in in vitro and in vivo model systems
Advice on research activities
In general this code should be used to characterise therapeutic targets rather than for their initial identification. It includes mechanism of action but should not be used to code studies where agonists or inhibitors are used as part of the methodology to understand the mechanism of other systems.
Includes mechanism of action and resistance to therapeutics. This includes characterisation of antibiotic resistance genes and mechanisms in bacteria which should not be coded as 2.2 Physical risks for cause of disease.
Includes studies predicting responses to therapies.
Includes studies of nutritional supplements used as treatments for disease.
Excludes studies focused on the potentially chemopreventative / health protective effects of specific nutrients, probiotics and nutritional supplements, which should be coded 3.3 Nutritional Prevention.
Official terminology
|
Full name of code |
Short name | Unique ID |
| 5.1 Pharmaceuticals | 5.1 Pharmaceutical |
HRCS_RA_5_1 |
Related external links
Common Scientific Outline (CSO) – 5.3 Systemic Therapies – Discovery and Development